MCID: HMN014
MIFTS: 54

Human Immunodeficiency Virus Infectious Disease

Categories: Immune diseases, Infectious diseases

Aliases & Classifications for Human Immunodeficiency Virus Infectious Disease

MalaCards integrated aliases for Human Immunodeficiency Virus Infectious Disease:

Name: Human Immunodeficiency Virus Infectious Disease 12 15
Hiv Infections 15

Classifications:



External Ids:

Disease Ontology 12 DOID:526
ICD9CM 34 042-042.99
MeSH 44 D015658
NCIt 50 C3108
SNOMED-CT 67 86406008
ICD10 32 B20
UMLS 71 C0019693

Summaries for Human Immunodeficiency Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.

MalaCards based summary : Human Immunodeficiency Virus Infectious Disease, also known as hiv infections, is related to acquired immunodeficiency syndrome and syphilis. An important gene associated with Human Immunodeficiency Virus Infectious Disease is CCR5 (C-C Motif Chemokine Receptor 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lercanidipine and Candesartan cilexetil have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and liver, and related phenotypes are cellular and hematopoietic system

Related Diseases for Human Immunodeficiency Virus Infectious Disease

Diseases related to Human Immunodeficiency Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 551)
# Related Disease Score Top Affiliating Genes
1 acquired immunodeficiency syndrome 32.4 TNF ITIH4 IL2 IL10 IFNG IFNA1
2 syphilis 31.5 CD4 CD209 CCR5 B2M
3 chlamydia 31.1 TNF IL10 IFNG
4 candidiasis 31.1 TNF IL2 IL10 IFNG
5 hepatitis c 31.0 TNF IL10 IFNG IFNA1 CCR5
6 hepatitis a 30.9 TNF IL10 IFNG IFNA1 CD4
7 viral hepatitis 30.9 TNF IL2 IL10 IFNG IFNA1
8 skin disease 30.8 TNF IL7 IL2 IL10 IFNG CD4
9 peripheral nervous system disease 30.8 TNF IL2 IL10 IFNG CXCR4 CXCL12
10 secondary syphilis 30.7 CD4 CD209 CCR5
11 oral hairy leukoplakia 30.7 ITIH4 IL10 CD4
12 pneumocystosis 30.7 TNF IL2 CD4 CCR5
13 human immunodeficiency virus type 1 30.7 TNF ITIH4 IL7 IL2 IL10 IFNG
14 trichomoniasis 30.7 TNF IL2 IL10 CD4 CCR5
15 bacterial pneumonia 30.7 TNF IL10 CD4 CCL3
16 periodontitis 30.7 TNF IL2 IL10 IFNG
17 toxoplasmosis 30.7 TNF IL10 IFNG CCR5 CCL3
18 uveitis 30.6 TNF IL2 IL10 IFNG CCR5 CCL4
19 bacterial infectious disease 30.6 TNF IL10 IFNG CD4 CCL4 CCL3
20 herpes zoster 30.6 TNF IL2 IL10 IFNG IFNA1 CD4
21 disease by infectious agent 30.5 TNF ITIH4 IL7 IL2 IL10 IFNG
22 lymphoma, non-hodgkin, familial 30.5 IL7 IL2 CXCR4 CXCL12 CD4 CD38
23 immune deficiency disease 30.5 TNF ITIH4 IL7R IL7 IL2 IL10
24 mycobacterium tuberculosis 1 30.5 TNF IL7 IL10 IFNG CD4 CD209
25 choroiditis 30.5 TNF IL10 IFNG CD4
26 iridocyclitis 30.5 TNF IL10 CD4
27 chronic inflammatory demyelinating polyradiculoneuropathy 30.5 IL10 IFNG CCL5 CCL4
28 anogenital venereal wart 30.5 IL2 IFNA1 CD4
29 keratoconjunctivitis 30.5 TNF IL2 IFNG CCL5
30 plague 30.5 TNF IL2 IL10 CD4 CCR5
31 aphthous stomatitis 30.5 TNF IL2 IL10 IFNG
32 genital herpes 30.5 IL10 CD4 CCL5
33 nervous system disease 30.4 TNF IL2 IL10 IFNG CD4
34 aseptic meningitis 30.4 TNF IL10 IFNG CCL3
35 prostatitis 30.4 TNF IL2 IL10 CCL3
36 endocarditis 30.4 TNF IL10 IFNG CCL4
37 meningoencephalitis 30.4 TNF IL10 CD4 CCL5 B2M
38 gingivitis 30.4 TNF IL2 IL10 IFNG CCL5
39 toxic shock syndrome 30.4 TNF IL2 IL10 IFNG
40 schistosomiasis 30.4 TNF IL2 IL10 IFNG CCL3
41 conjunctivitis 30.4 TNF IL7 IL2 IL10 IFNG
42 erythema nodosum 30.4 TNF IL10 IFNG
43 dermatitis 30.4 TNF IL2 IL10 IFNG CD4 CCL5
44 chickenpox 30.4 TNF IL2 IL10 IFNG IFNA1 CD4
45 pulmonary tuberculosis 30.4 TNF IL2 IL10 IFNG CCL4 CCL3
46 exanthem 30.4 TNF IL2 IL10 IFNG IFNA1 CD4
47 leprosy 3 30.4 TNF IL2 IL10 IFNG CD4 CD209
48 retinal detachment 30.4 TNF IL10 IFNG CXCL12 CCL4
49 melioidosis 30.4 TNF IL10 IFNG
50 stomatitis 30.4 TNF IL2 IL10 IFNG IFNA1 CD4

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Infectious Disease:



Diseases related to Human Immunodeficiency Virus Infectious Disease

Symptoms & Phenotypes for Human Immunodeficiency Virus Infectious Disease

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Infectious Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 B2M CCR5 CD38 CD4 CD9 CXCL12
2 hematopoietic system MP:0005397 10.24 B2M CCL5 CCR5 CD209 CD38 CD4
3 endocrine/exocrine gland MP:0005379 10.18 B2M CD38 CD4 CD9 CXCR4 IFNG
4 immune system MP:0005387 10.17 B2M CCL5 CCR5 CD38 CD4 CD9
5 digestive/alimentary MP:0005381 10.03 B2M CCR5 CD4 CXCR4 IFNG IL10
6 liver/biliary system MP:0005370 9.86 B2M CCR5 CXCL12 IFNG IL10 IL2
7 neoplasm MP:0002006 9.85 B2M CCR5 CD9 CXCR4 IFNG IL10
8 no phenotypic analysis MP:0003012 9.5 CD4 CXCL12 IFNG IL10 IL2 IL7
9 reproductive system MP:0005389 9.32 B2M CCR5 CD9 CXCL12 CXCR4 IFNG

Drugs & Therapeutics for Human Immunodeficiency Virus Infectious Disease

Drugs for Human Immunodeficiency Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 792)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
2
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
3
Ezetimibe Approved Phase 4 163222-33-1 150311
4
Fenofibrate Approved Phase 4 49562-28-9 3339
5
Fosamprenavir Approved Phase 4 226700-79-4 131536
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
8
Didanosine Approved Phase 4 69655-05-6 50599
9
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027
10
Cobicistat Approved Phase 4 1004316-88-4
11
Zinc Approved, Investigational Phase 4 7440-66-6 32051
12
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
13
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
14
Lactitol Approved, Investigational Phase 4 585-86-4 157355
15
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
16
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
17
Sulfamethoxazole Approved Phase 4 723-46-6 5329
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
20
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
21
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
22
Famotidine Approved Phase 4 76824-35-6 3325
23
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
24
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
25
Metronidazole Approved Phase 4 443-48-1 4173
26
Pravastatin Approved Phase 4 81093-37-0 54687
27
Testosterone Approved, Investigational Phase 4 58-22-0 6013
28
Echinacea Approved, Experimental Phase 4
29
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
30
Temazepam Approved, Investigational Phase 4 846-50-4 5391
31
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
32
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
33
Polyestradiol phosphate Approved Phase 4 28014-46-2
34
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
35
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
36
Prothionamide Approved, Investigational Phase 4 14222-60-7 666418
37
Ethionamide Approved Phase 4 536-33-4 2761171
38
Kanamycin Approved, Investigational, Vet_approved Phase 4 59-01-8, 8063-07-8 6032
39
Capreomycin Approved Phase 4 11003-38-6 3000502
40
Cycloserine Approved Phase 4 68-41-7 401 6234
41
Clarithromycin Approved Phase 4 81103-11-9 84029
42
Atovaquone Approved Phase 4 95233-18-4 74989
43
Proguanil Approved Phase 4 500-92-5 4923
44
Norethindrone Approved Phase 4 68-22-4 6230
45
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
46
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
47
Zoledronic Acid Approved Phase 4 118072-93-8 68740
48
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
49
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
50
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596

Interventional clinical trials:

(show top 50) (show all 5089)
# Name Status NCT ID Phase Drugs
1 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
2 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
3 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
4 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
5 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
6 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
7 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
8 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
9 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
10 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
11 Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS) Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
12 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
13 A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
14 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
15 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
16 Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study Unknown status NCT03732625 Phase 4 Raltegravir
17 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
18 Bictegravir, Emtricitabine and Tenofovir Alafenamide in Transwomen for Optimization of ART: The (mo)BETTA Trial Unknown status NCT03348163 Phase 4 B/FTC/TAF;Current ART
19 Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
20 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
21 Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
22 A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
23 Effect of a Treatment Switch From Protease Inhibitor to Raltegravir-based ART on Myeloid Cell Inflammation in HIV-infected Patients. Unknown status NCT02691065 Phase 4 Integrase Inhibitor
24 Randomized Controlled Trial to Compare the Immunogenicity of Intramuscular Versus Intradermal Trivalent Inactivated Split Virion Influenza Vaccine in HIV-infected Men Who Have Sex With Men in Bangkok, Thailand Unknown status NCT01538940 Phase 4
25 Immunogenicity and Safety of 4- vs. 3-standard Doses HBV Vaccination in HIV-infected Adults With Isolated Anti-HBc Antibody Unknown status NCT03212911 Phase 4
26 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study. Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
27 Study of the Immunogenicity and Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Adults Unknown status NCT03041051 Phase 4
28 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
29 Immunologic Response of Hepatitis B Single Dose Versus 3-dose Series in Previously Vaccinated HIV-infected Adults at Maharaj Nakorn Chiang Mai Hospital: A Randomized Controlled Trial Unknown status NCT03219203 Phase 4
30 The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Unknown status NCT03205566 Phase 4 Raltegravir 400Mg Tab;Lamivudine 150Mg Tablet
31 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
32 Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml Unknown status NCT01453933 Phase 4 raltegravir
33 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
34 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
35 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
36 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
37 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
38 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
39 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
40 Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial). Unknown status NCT02337322 Phase 4 Dolutegravir;Darunavir/r
41 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
42 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
43 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
44 Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial Completed NCT02431975 Phase 4 Nevirapine;Zidovudine;Lamivudine;LPV/r
45 Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time Completed NCT00192660 Phase 4 Lamivudine;Stavudine;Didanosine;Zidovudine;Tenofovir;Abacavir;Efavirenz (EFV);Nevirapine;Indinavir;Saquinavir;Amprenavir;Ritonavir;Nelfinavir;Tipranavir;enfuvirtide (T20)
46 Open Label Study of Lung and Serum Immunoglobulin Responses to 7-Valent Pneumococcal Conjugate Vaccine in HIV Infected and Non-HIV Infected Malawian Adults Completed NCT00371878 Phase 4
47 Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation Completed NCT03314064 Phase 4 Dolutegravir 50 mg
48 Randomised, Openlabel Study Evaluating Efficacy and Safety of Maraviroc as a Switch for Either NRTI or PI/r in HIV-1 Infected Individuals With Stable, Well-Controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of cART Completed NCT01384682 Phase 4 Maraviroc
49 Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (Impact of HAART to Prevent Pediatric AIDS in Rural Zambia). Completed NCT00753324 Phase 4 Routine three-drug antiretroviral prophylaxis
50 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4

Search NIH Clinical Center for Human Immunodeficiency Virus Infectious Disease

Genetic Tests for Human Immunodeficiency Virus Infectious Disease

Anatomical Context for Human Immunodeficiency Virus Infectious Disease

MalaCards organs/tissues related to Human Immunodeficiency Virus Infectious Disease:

40
T Cells, Bone, Liver, Endothelial, Bone Marrow, Monocytes, Lymph Node

Publications for Human Immunodeficiency Virus Infectious Disease

Articles related to Human Immunodeficiency Virus Infectious Disease:

(show top 50) (show all 6785)
# Title Authors PMID Year
1
Rapid detection of HIV-1 p24 antigen using magnetic immuno-chromatography (MICT). 61 54
19482361 2009
2
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. 61 54
19535523 2009
3
Expression and production of human interleukin-7 in insect cells using baculovirus expression vector system (BEVS). 54 61
18546077 2008
4
Emerging antiviral drugs. 54 61
18764719 2008
5
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. 54 61
18096673 2008
6
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. 54 61
16439866 2006
7
Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. 54 61
16438645 2006
8
RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. 54 61
16353935 2005
9
Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors. 61 54
14741421 2004
10
Polymorphisms of CCR5 gene in a southern Chinese population and their effects on disease progression in HIV infections. 61 54
12461425 2002
11
Oral mucosal immunity and HIV infection: current status. 54 61
12164661 2002
12
Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. 61 54
11237281 2001
13
Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. 61 54
11101052 2000
14
Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. 61 54
10195751 1999
15
[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]. 61 54
10189669 1999
16
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. 54 61
10231014 1999
17
Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. 54 61
9612607 1998
18
New perspectives for the treatment of HIV infections. 61 54
9646721 1998
19
The role of biological response modifiers on apoptosis in HIV infections and AIDS. 61 54
17451286 1996
20
Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. 54 61
9079375 1996
21
Differential effects of human immunodeficiency virus type 1 envelope protein gp120 on interferon production by mononuclear cells from adults and neonates. 54 61
7583919 1995
22
Zinc and immune function. 54 61
7478075 1995
23
Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II. 54 61
7946101 1994
24
[Interferon-gamma. Therapy of recurrent furunculosis in HIV infections]. 61 54
8104915 1993
25
Effectiveness of assays for antibodies to HIV and p24 antigen to detect very recent HIV infections in blood donors. The Retrovirus Study Group of the French Society of Blood Transfusion. 61 54
1492941 1992
26
Chemo-metric assisted UV-spectrophotometric methods for simultaneous estimation of Darunavir ethanolate and Cobicistat in binary mixture and their tablet formulation. 61
33422867 2021
27
Willingness to Participate in At-Home HIV Testing Among Young Adults Who Use Opioids in Rural Appalachia. 61
32910353 2021
28
Evidence for HIV transmission across key populations: a longitudinal analysis of HIV and AIDS rates among Black people who inject drugs and Black heterosexuals in 84 large U.S. metropolitan areas, 2008-2016. 61
33065266 2021
29
Sexual Behavior and Its Determinants During COVID-19 Restrictions Among Men Who Have Sex With Men in Amsterdam. 61
33230027 2021
30
A Surveillance Data-Based Model System for Assessing the Effects of HIV Intervention and Prevention Strategies. 61
31688740 2021
31
The Prevalence of HIV Among Men Who Have Sex With Men (MSM) and Young MSM in Latin America and the Caribbean: A Systematic Review. 61
33587242 2021
32
HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. 61
33561143 2021
33
Transmitted Drug Resistance among HIV-1 drug-naïve patients in Greece. 61
33592343 2021
34
mHealth Strategies Related to HIV Postexposure Prophylaxis Knowledge and Access: Systematic Literature Review, Technology Prospecting of Patent Databases, and Systematic Search on App Stores. 61
33591289 2021
35
Leaving no one behind? An equity analysis of the HIV care cascade among a cohort of people living with HIV in Manitoba, Canada. 61
33541302 2021
36
Phylogenetic Analysis of Sequences in the HIV Database Revealed Multiple Potential Circulating Recombinant Forms in China. 61
33390081 2021
37
Mathematical Model Impact Analysis of a Real-Life Pre-exposure Prophylaxis and Treatment-As-Prevention Study Among Female Sex Workers in Cotonou, Benin. 61
33105397 2021
38
HIV pre-exposure prophylaxis (PrEP) knowledge, attitudes and perceptions of sexual health risk in an age of STI antimicrobial resistance. 61
33534406 2021
39
Physician network connections to specialists and HIV quality of care. 61
33543503 2021
40
Exploring the potency of currently used drugs against HIV-1 protease of subtype D variant by using multiscale simulations. 61
32000612 2021
41
Seronegative Villous Atrophy in Children: Clinical and Immunohistochemical Features. 61
32833891 2021
42
Preparing for PrEP; the cost of delaying universal access in England. 61
32366606 2021
43
Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. 61
33572409 2021
44
Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. 61
32604408 2021
45
Modular Approaches to Understand the Immunobiology of Human Immunodeficiency Virus Latency. 61
33600238 2021
46
Consequences of COVID-19 crisis for persons with HIV: the impact of social determinants of health. 61
33546659 2021
47
Anxiety and depression among women living with HIV in Kazakhstan. 61
31983231 2021
48
"I went in there, had a bit of an issue with those folks": everyday challenges of heterosexual African, Caribbean and black (ACB) men in accessing HIV/AIDS services in London, Ontario. 61
33557794 2021
49
Cost-Effectiveness of HRSA's Ryan White HIV/AIDS Program? 61
33093330 2021
50
An in-depth analysis of novel combinatorial drug therapy via nanocarriers against HIV/AIDS infection and their clinical perspectives: a systematic review. 61
33460332 2021